Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
M-Cdk Drives Transition Into Mitosis02:15

M-Cdk Drives Transition Into Mitosis

Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
Antiviral Nucleoside Inhibitors01:22

Antiviral Nucleoside Inhibitors

Antiviral Nucleoside InhibitorsAntiviral nucleoside inhibitors are structural analogs of natural nucleosides that interfere with viral DNA or RNA synthesis. These compounds selectively target viral polymerases due to their resemblance to host nucleosides, thereby disrupting viral genome replication.Mechanism of Acyclovir ActionAcyclovir is a guanosine analog with a three-carbon acyclic side chain. It selectively targets herpes simplex virus type 1 (HSV-1), herpes simplex virus type 2 (HSV-2),...
Protein Kinases and Phosphatases02:54

Protein Kinases and Phosphatases

Proteins undergo chemical modifications that trigger changes in the charge, structure, and conformation of the proteins. Phosphorylation, acetylation, glycosylation, nitrosylation, ubiquitination, lipidation, methylation, and proteolysis are various protein modifications that regulate protein activity. Such modifications are usually enzyme-driven.
Protein kinases
Many proteins in the cell are regulated by phosphorylation, the addition of a phosphate group. A family of enzymes called kinases...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Prognostic outcomes of adjuvant chemotherapy in postoperative patients with cancer undergoing hemodialysis versus non-hemodialysis patients: a retrospective nationwide cohort study.

BMC cancer·2026
Same author

Genomic Profiling of Cancerous Areas, Dysplasia, and Background Mucosa in Ulcerative Colitis-associated Colorectal Cancer.

Anticancer research·2026
Same author

Genomic and Transcriptomic Analysis of High-Grade Endometrial Carcinoma Reveals Biological Heterogeneity and Molecular Classification Challenges.

Cancer research communications·2026
Same author

Study protocol for a phase I investigator-initiated clinical trial of E7820 in Japanese patients with unresectable solid tumours: CIRCUS trial (NCCH2303).

Japanese journal of clinical oncology·2026
Same author

Author Correction: Maintenance of R-loop structures by phosphorylated hTERT preserves genome integrity.

Nature cell biology·2026
Same author

Late-Onset Bilateral Malignant Ciliary Body Medulloepithelioma in an Adult.

Pathology international·2026

Related Experiment Video

Updated: Jun 8, 2026

Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries
08:49

Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries

Published on: January 22, 2019

[Cytoplasmic kinase inhibitors].

Hiroyuki Mano1

  • 1Division of Functional Genomics, Jichi Medical University.

Nihon Rinsho. Japanese Journal of Clinical Medicine
|October 20, 2010
PubMed
Summary

Targeting activated protein kinases, through mutations or fusions, offers a promising strategy for cancer treatment. Kinase inhibitors are being developed for various cancers, showing potential for tumor eradication.

Area of Science:

  • Biochemistry
  • Oncology
  • Pharmacology

Background:

  • Protein kinases regulate cell proliferation.
  • Aberrant protein kinase activity (mutations/fusions) is common in human cancers.
  • Targeting these kinases is a validated therapeutic strategy.

Purpose of the Study:

  • To review the role of protein kinases in cancer.
  • To highlight the therapeutic potential of kinase inhibitors.
  • To discuss ongoing clinical trials for specific kinase inhibitors.

Main Methods:

  • Literature review of protein kinase function in cancer.
  • Analysis of clinical trial data for kinase inhibitors.
  • Examination of specific examples like imatinib, EML4-ALK, JAK2, and BRAF inhibitors.

More Related Videos

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors
10:33

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors

Published on: October 26, 2015

Identification of Novel CK2 Kinase Substrates Using a Versatile Biochemical Approach
11:11

Identification of Novel CK2 Kinase Substrates Using a Versatile Biochemical Approach

Published on: February 21, 2019

Related Experiment Videos

Last Updated: Jun 8, 2026

Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries
08:49

Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries

Published on: January 22, 2019

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors
10:33

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors

Published on: October 26, 2015

Identification of Novel CK2 Kinase Substrates Using a Versatile Biochemical Approach
11:11

Identification of Novel CK2 Kinase Substrates Using a Versatile Biochemical Approach

Published on: February 21, 2019

Main Results:

  • Imatinib mesylate demonstrates efficacy against ABL tyrosine kinase in chronic myeloid leukemia.
  • Clinical trials show promise for inhibitors targeting EML4-ALK, JAK2, and BRAF in various cancers.
  • Activated kinases represent viable targets for novel cancer therapies.

Conclusions:

  • Targeting activated protein kinases is a successful approach in cancer therapy.
  • Kinase inhibitors are promising drugs for treating human cancers.
  • Further development of kinase inhibitors holds significant therapeutic potential.